Both in Pharmaceuticals
Bicara Therapeutics vs PUMA BIOTECHNOLOGY
Over the past year BCAX returned −42.7% and PBYI returned +103.6%; their daily moves had a correlation of 0.24.
BCAX −42.7% PBYI +103.6%Growth of $1, one year, split-adjusted
| Metric | BCAX | PBYI |
|---|---|---|
| Price | $9.16 | $10.26 |
| Market cap | $606.1M | $529.6M |
| Today | +15.51% | +0.79% |
| 1 month | −47.0% | +6.1% |
| 6 months | −60.4% | +39.6% |
| Year to date | −45.6% | +72.4% |
| 1 year | −43.6% | +101.2% |
| Revenue growth (YoY) | — | +7.8% |
| Gross margin | — | 77.9% |
| Net margin | — | 14.5% |
| P/E (TTM) | — | 19.8× |
| Price / sales | — | 2.3× |
| Net cash | $497.3M | $93.9M |
| Dividend yield | — | — |
| Volatility (60d) | 135.8% | 39.6% |
| Short % of float | 23.9% | 11.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).